The pharmaco-economics of atypical antipsychotics

References

• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Caiman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–13
   PubMedGoogle Scholar
• Dunn C J, Fitton A. Sertindole. CNS Drugs 1996; 5: 224–30
   Google Scholar
• Tollefson G D, Beasley C, Tran P V, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65
   PubMed Web of Science ®Google Scholar
• Boyer P, Lecrubier Y, Puech A J, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995; 166: 68–72
   PubMed Web of Science ®Google Scholar
• Lieberman J A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rational hypothesis. J Clin Psychiatry 1996; 57(Suppl 11)68–71
   PubMed Web of Science ®Google Scholar
• Knapp M RJ. Cost-effectiveness in the treatment of schizophrenia. Eur Psychiatry 1996; 11: 137–43
   PubMedGoogle Scholar
• Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol 1997; 43: 343–8
   PubMed Web of Science ®Google Scholar
• Drummond M F, Stoddart G L, Torrance G W. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford 1987
   Google Scholar
• Robinson R. Economic evaluation and health care: what does it mean. Br Med J 1993; 307: 670–3
   PubMed Web of Science ®Google Scholar
• Davies L M, Drummond M F. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165(suppl 25)18–21
   Google Scholar
• Revicki D A, Luce B R, Weschler J M. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4
   PubMedGoogle Scholar
• Frank R G. Clozapine's cost benefits [Letter]. Hosp Community Psychiatry 1991; 42: 92
   PubMedGoogle Scholar
• Goldman H H. Clozapine's cost benefits [Letter]. Hosp Community Psychiatry 1991; 42: 92–3
   PubMedGoogle Scholar
• Revicki D A, Luce B R, Weschler J M, et al. Clozapine's cost benefits [Letter]. Hosp Community Psychiatry 1991; 42: 93–4
   Google Scholar
• Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 882–5
   PubMedGoogle Scholar
• Frankenburg F R, Zanarini M C, Cole J O, et al. Hospitalisation rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992; 4: 247–50
   Google Scholar
• Meltzer H Y, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8
   PubMed Web of Science ®Google Scholar
• Schiller M, Hargreaves W A. Clozapine's cost effectiveness [Letter]. Am J Psychiatry 1995; 152: 151–2
   PubMed Web of Science ®Google Scholar
• Essock S M. Clozapine's cost effectiveness [Letter]. Am J Psychiatry 1995; 152: 152
   PubMedGoogle Scholar
• Meltzer H Y, Cola P. Dr Meltzer and Mr Cola reply [Letter]. Am J Psychiatry 1995; 152: 153–4
   Google Scholar
• Davies L M, Drummond M F. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42
   PubMed Web of Science ®Google Scholar
• Matheson L A, Cook H M, McKenna P, et al. Value for money care for patients with schizophrenia. Br J Med Economics 1994; 7: 25–34
   Google Scholar
• Shepherd M, Watt D, Falloon I, et al. The natural history of schizophrenia; a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychiatr Med 1989; 15: 1–46
   Google Scholar
• Reid W H, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261–4
   PubMedGoogle Scholar
• Jonsson D, Wålinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199–201
   PubMedGoogle Scholar
• Essock S M. Clozapine eligibility among State hospital patients. Schizophr Bull 1996; 22: 15–25
   PubMed Web of Science ®Google Scholar
• Aitchison K J, Kerwin R W. Cost-effectiveness of clozapine: a UK clinic-based study. Br J Psychiatry 1997; 171: 125–30
   PubMedGoogle Scholar
• Robert G, Kennedy P. Establishing cost-effectiveness of atypical neuroleptics. Br J Psychiatry 1997; 171: 103–4
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809–15
   PubMed Web of Science ®Google Scholar
• Geronimi-Ferret D, Lesay M, Barges-Bertocchio M H, et al. Evaluation médico-économique du traitement par la clozapine versus les traitements neuroleptiques antérieurs. L'Encéphale Sp 1997; 1V: 24–31
   Google Scholar
• Reid W H, Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a State mental health care system. J Clin Psychiatry 1998; 59: 189–94
   PubMed Web of Science ®Google Scholar
• Laker M K, Duffett R S, Cookson J C. Long-term outcome with clozapine: comparison of patients continuing and discontinuing treatment. Int Clin Psychopharmacol 1998; 13: 75–8
   PubMedGoogle Scholar
• Pollack S, Woerner M G, Howard A, et al. Clozapine reduces rehospitalizaion among schizophrenia patients. Psychopharmacol Bull 1998; 34: 89–92
   PubMedGoogle Scholar
• Addington D E, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26
   PubMed Web of Science ®Google Scholar
• Guest J F, Hart W M, Cookson R F, et al. Pharmaco-economic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Economics 1996; 10: 59–67
   Google Scholar
• Albright P S, Livingstone S, Keegan D L, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Drug Invest 1996; 11: 289–99
   Web of Science ®Google Scholar
• Chouinard G, Albright P S. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997; 17: 298–307
   PubMed Web of Science ®Google Scholar
• Viale G, Mechling L, Maislin G, et al. Impact of risperidone on the use of mental health care resources. Psychiatric Services 1997; 48: 1153–9
   PubMed Web of Science ®Google Scholar
• Finley P R, Sommer B R, Corbitt J L, et al. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998; 34: 75–81
   PubMedGoogle Scholar
• Ginsberg G, Shani S, Lev B. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. Pharmacoeconomics 1998; 13: 231–41
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Nabulsi A, Silber C, et al. Reduction of hospital days in sertindole treated patients: one year findings. Schizophr Res 1997; 24: 201–2
   Google Scholar
• Glazer W M, Johnstone B M. Pharmacoeconomic evaluation of antipsychotic therapy for Schizophrenia. J Clin Psychiatry 1997; 58(suppl 10)50–4
   PubMedGoogle Scholar
• Sacristan J A, Gómez J C, Martin J, et al. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. Clin Drug Investigation 1998; 15: 29–35
   PubMedGoogle Scholar
• Palmer C S, Revicki D A, Genduso L A, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 1998; 4: 345–55
   PubMed Web of Science ®Google Scholar
• Beasley C M, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol acute phase results of the North American double-blind trial. Neuropsychopharmacology 1996; 14: 111–23
   PubMed Web of Science ®Google Scholar
• Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: A comparison of olanzapine and haloperidol. Pharmacoeconomics 1998; 13: 575–88
   PubMedGoogle Scholar
• Souaˇtre E, Martin P, Lecanu J P, et al. Évaluation médicoéconomique des neuroleptiques dans la schizophrénie: Amisulpride versus halopéridol. L'Encéphale 1992; 18: 263–9
   PubMedGoogle Scholar
• Prakash A, Lamb H M. Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998; 9: 153–75
   Google Scholar
• Byrom B D, Garratt C J, Kilpatrick A T. Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach. Int J Psych Clin Pract 1998; 2: 129–38
   PubMedGoogle Scholar
• Rosenheck R, Massari L, Frisman L. Who should receive high-cost mental health treatment and for how long. Schizophr Bull 1993; 19: 843–52
   PubMed Web of Science ®Google Scholar
• Umbricht D SG, Lieberman J A, Kane J M. The clinical efficacy of clozapine in the treatment of schizophrenia. Rev Contemp Pharmacother 1995; 6: 165–86
   Google Scholar